A Phase 4 interventional study of Tenofovir disoproxil fumarate in Hepatitis B, Chronic, sponsored by GlaxoSmithKline. Completed at 19 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-14.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 14th largest by enrollment, is one of 7 that started in 2015, is one of 22 in phase 4, and was the 33rd registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 7 started in 2015.
This study's enrollment of 197 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
30 studies in Hepatitis B, Chronic by GlaxoSmithKline: 1 open now, 2 under way, none of them phase 3. Of 28 finished, 18 (64%) have results posted.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2015, is one of 10 in phase 4, and was the 19th registered.
GlaxoSmithKline’s Hepatitis B, Chronic studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 30 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC). Active hepatitis B virus (HBV) replication is the key driver of liver injury and disease progression. Majority of Chinese patients are infected with genotype B and C HBV, which is different from Caucasian counterparts. This prospective multi-center cohort open-label study is designed to investigate the long-term effect of TDF on prevention of HCC and disease progression as well as to evaluate the efficacy and safety of long-term TDF in Chinese CHB subjects with advanced liver diseases. The study will enrol 240 subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
Drug: Tenofovir disoproxil fumarate
White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with "GILEAD" and "4331" on one side of the tablet.
Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240
The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).
Time frame: Week 240
Percentage of Participants With Disease Progression at Week 240
Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/esophageal varices; 6) hepatocellular carcinoma; 7)liver-related death.
Time frame: Week 240
Number of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144 and Week 192
The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).
Time frame: Week 48, Week 96, Week 144 and Week 192
Percentage of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144, Week 192 and Week 240
The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).The cumulative percentage of participants with newly diagnosed Hepatocellular Carcinoma has been presented along with 95% confidence interval (CI) (Wald method).
Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of Participants With Disease Progression at Week 48, Week 96, Week 144, Week 192 and Week 240
Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/oesophageal varices; 6) hepatocellular carcinoma; 7) liver-related death. The cumulative percentage of participants with disease progression has been presented along with 95% CI (Wald method).
Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240
Mean Change From Baseline in Liver Stiffness Measure at Week 48, Week 96, Week 144, Week 192 and Week 240
Liver stiffness measure was obtained by a non-invasive transient elastography using FibroScan. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline is defined as post-dose visit value minus Baseline value
Time frame: Baseline (Day 0), Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Units Per Milliliter (IU/mL) at Weeks 48, 96, 144, 192 and 240
Serum samples were collected for the analysis of HBV DNA levels using Roche Cobas Taqman HBV test. Confidence interval was calculated by normal approximation and continuity correction method.
Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Logarithm to the Base 10 (Log 10) Serum HBV DNA
Serum samples were collected for the analysis of HBV DNA levels. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48, Week 96, Week 144, Week 192 and Week 240 in Participants Who Had Abnormal ALT at Baseline
Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization is defined as ALT outside the normal range at Baseline and within the normal range at Week 48, Week 96, Week 144, Week 192 and Week 240. Normal range of ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, 144, 192 and 240 in participants who had abnormal ALT at Baseline (Day 0) have been presented. Confidence interval was calculated using normal approximation and continuity correction method.
Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240.
Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss and HBeAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. Confidence interval was calculated using normal approximation and continuity correction method.
Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240
Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.
Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of Participants Who Experienced Viral Breakthrough
Viral breakthrough was defined as \>=1 log10 increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of Participants who experienced viral breakthrough at Week 48, Week 96, Week 144, Week 192 and Week 240 is presented.
Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of Participants With Histological Improvement at Week 216
The Knodell scoring system, also called the Histologic Activity Index (HAI), classifies liver biopsy specimens according to scores into 4 categories of histologic features: (I) Periportal or periseptal interface hepatitis (piecemeal necrosis) (scores from 0, 1, 2, 3, 4 or 10); (II) Confluent necrosis (scores from 0, 1, 3, 4, 5, 6 or 10); (III) Focal (spotty) lytic necrosis, apoptosis and focal inflammation (scores from 0, 1, 2, 3, 4 or 10); (IV) Portal inflammation (scores from 0, 1, 2, 3, 4 or 10). Histological improvement is considered as a reduction of two or more points in the Knodell necroinflammatory score with no increase in fibrosis.
Time frame: Week 216
Percentage of Participants With Cirrhosis Reversal at Week 216
Cirrhosis reversal was defined as a reduction of one or more points in the Ishak score with no evidence of cirrhosis. The Ishak liver fibrosis score ranges from 0 indicating no fibrosis to 6 indicating cirrhosis.
Time frame: Week 216
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE that occurred on or after the first dose date of study drug. SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events possible drug-induced liver injury with hyperbilirubinemia.
Time frame: Up to Week 240
Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, WBC, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Hemoglobin (Hb)
Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Red Blood Cells (RBC)
Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)
Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Serum Creatinine
Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Chemistry Parameters: Albumin and Total Protein
Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridion, Phosphorus, Calcium and Fasting Blood Glucose
Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridion, phosphorus,calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Chemistry Parameters: Creatinine Clearance Rate
Blood samples were collected to analyze the chemistry parameters: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Change From Baseline in Chemistry Parameters: Estimated Glomerular Filtration Rate (eGFR)
Blood samples were collected to analyze the chemistry parameters: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
This study was conducted to evaluate the efficacy and safety of 300 milligram (mg) Tenofovir Disoproxil Fumarate (TDF) therapy in Chinese chronic hepatitis B (CHB) participants with advanced fibrosis and compensated cirrhosis
| Milestone | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Started | 197 |
| Completed | 161 |
| Not completed | 36 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Lost to follow-up | 15 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Physician decision | 3 |
| Withdrew: Death | 2 |
| Withdrew: Pregnancy | 4 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Treatment interruptions of ≥28 days | 1 |
The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).
| Events per person-year | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240 | 6.045 |
Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/esophageal varices; 6) hepatocellular carcinoma; 7)liver-related death.
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Percentage of Participants With Disease Progression at Week 240 | 7.2 |
The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).
| Participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48 | 0 |
| Week 96 | 0 |
| Week 144 | 4 |
| Week 192 | 9 |
The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).The cumulative percentage of participants with newly diagnosed Hepatocellular Carcinoma has been presented along with 95% confidence interval (CI) (Wald method).
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48 | 0 (NA to NA) |
| Week 96 | 0 (NA to NA) |
| Week 144 | 2.1 (0.0 to 4.3) |
| Week 192 | 4.6 (1.4 to 7.8) |
| Week 240 | 5.6 (2.1 to 9.1) |
Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/oesophageal varices; 6) hepatocellular carcinoma; 7) liver-related death. The cumulative percentage of participants with disease progression has been presented along with 95% CI (Wald method).
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48 | 2.1 (0.0 to 4.3) |
| Week 96 | 2.6 (0.1 to 5.0) |
| Week 144 | 4.1 (1.1 to 7.1) |
| Week 192 | 7.2 (3.3 to 11.1) |
| Week 240 | 7.2 (3.3 to 11.1) |
Liver stiffness measure was obtained by a non-invasive transient elastography using FibroScan. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline is defined as post-dose visit value minus Baseline value
| Kilopascals | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=182 | -3.3 ± 4.84 |
| Week 96, n= 176 | -4.7 ± 5.60 |
| Week 144, n= 175 | -5.1 ± 5.85 |
| Week 192, n=167 | -5.1 ± 7.82 |
| Week 240, n= 131 | -6.2 ± 5.55 |
Serum samples were collected for the analysis of HBV DNA levels using Roche Cobas Taqman HBV test. Confidence interval was calculated by normal approximation and continuity correction method.
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=191 | 81.2 (75.3 to 87.0) |
| Week 96, n=188 | 88.8 (84.1 to 93.6) |
| Week 144, n=185 | 94.1 (90.4 to 97.7) |
| Week 192, n=174 | 97.7 (95.2 to 100.0) |
| Week 240, n=160 | 99.4 (97.8 to 100.0) |
Serum samples were collected for the analysis of HBV DNA levels. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Log 10 (IU/mL) | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=191 | -4.2 ± 1.40 |
| Week 96, n=188 | -4.3 ± 1.44 |
| Week 144, n=185 | -4.3 ± 1.48 |
| Week 192, n=174 | -4.2 ± 1.50 |
| Week 240, n=160 | -4.3 ± 1.46 |
Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization is defined as ALT outside the normal range at Baseline and within the normal range at Week 48, Week 96, Week 144, Week 192 and Week 240. Normal range of ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, 144, 192 and 240 in participants who had abnormal ALT at Baseline (Day 0) have been presented. Confidence interval was calculated using normal approximation and continuity correction method.
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=97 | 63.9 (53.8 to 74.0) |
| Week 96, n= 97 | 66.0 (56.0 to 75.9) |
| Week 144, n=96 | 70.8 (61.2 to 80.4) |
| Week 192, n=93 | 82.8 (74.6 to 91.0) |
| Week 240, n=87 | 82.8 (74.2 to 91.3) |
Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss and HBeAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. Confidence interval was calculated using normal approximation and continuity correction method.
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, HBeAg Loss, n=94 | 18.1 (9.8 to 26.4) |
| Week 48, HBeAg Seroconversion, n=94 | 9.6 (3.1 to 16.1) |
| Week 96, HBeAg , n=94 | 33.0 (22.9 to 43.0) |
| Week 96, HBeAg Seroconversion, n=94 | 14.9 (7.2 to 22.6) |
| Week 144, HBeAg Loss, n=90 | 35.6 (24.5 to 45.1) |
| Week 144, HBeAg Seroconversion, n=90 | 14.4 (6.5 to 21.8) |
| Week 192, HBeAg Loss, n=90 | 47.8 (36.4 to 58.1) |
| Week 192, HBeAg Seroconversion, n=90 | 16.7 (8.3 to 24.7) |
| Week 240, HBeAg Loss, n=82 | 51.2 (38.7 to 61.3) |
| Week 240, HBeAg Seroconversion, n=82 | 23.2 (13.1 to 32.2) |
Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.
| Percentage of Participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, HBsAg Loss, n=97 | 1.0 (0.0 to 3.6) |
| Week 48, HBsAg Seroconversion, n=97 | 1.0 (0.0 to 3.6) |
| Week 96, HBsAg , n=93 | 0 (0.0 to 0.5) |
| Week 96, HBsAg Seroconversion, n=93 | 0 (0.0 to 0.5) |
| Week 144, HBsAg Loss, n=93 | 3.2 (0.0 to 7.4) |
| Week 144, HBsAg Seroconversion, n=93 | 0 (0.0 to 0.5) |
| Week 192, HBsAg Loss, n=89 | 4.5 (0.0 to 9.4) |
| Week 192, HBsAg Seroconversion, n=89 | 2.2 (0.0 to 5.9) |
| Week 240, HBsAg Loss, n=77 | 5.2 (0.0 to 10.8) |
| Week 240, HBsAg Seroconversion, n=77 | 1.3 (0.0 to 4.5) |
Viral breakthrough was defined as \>=1 log10 increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of Participants who experienced viral breakthrough at Week 48, Week 96, Week 144, Week 192 and Week 240 is presented.
| Percentage of Participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=195 | 0 (NA to NA) |
| Week 96, n=195 | 0 (NA to NA) |
| Week 144, n=185 | 0.5 (0.0 to 1.9) |
| Week 192, n=180 | 1.1 (0.0 to 2.9) |
| Week 240, n=161 | 0.6 (0.0 to 2.1) |
The Knodell scoring system, also called the Histologic Activity Index (HAI), classifies liver biopsy specimens according to scores into 4 categories of histologic features: (I) Periportal or periseptal interface hepatitis (piecemeal necrosis) (scores from 0, 1, 2, 3, 4 or 10); (II) Confluent necrosis (scores from 0, 1, 3, 4, 5, 6 or 10); (III) Focal (spotty) lytic necrosis, apoptosis and focal inflammation (scores from 0, 1, 2, 3, 4 or 10); (IV) Portal inflammation (scores from 0, 1, 2, 3, 4 or 10). Histological improvement is considered as a reduction of two or more points in the Knodell necroinflammatory score with no increase in fibrosis.
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Percentage of Participants With Histological Improvement at Week 216 | 45.2 (26.0 to 64.3) |
Cirrhosis reversal was defined as a reduction of one or more points in the Ishak score with no evidence of cirrhosis. The Ishak liver fibrosis score ranges from 0 indicating no fibrosis to 6 indicating cirrhosis.
| Percentage of participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Percentage of Participants With Cirrhosis Reversal at Week 216 | 41.9 (23.0 to 60.9) |
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE that occurred on or after the first dose date of study drug. SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events possible drug-induced liver injury with hyperbilirubinemia.
| Participants | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Any TEAEs | 139 |
| Serious TEAE | 34 |
| Non-serious TEAE | 129 |
Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, WBC, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| 10^9 cells per liter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, WBC, n=191 | 0.02 ± 1.264 |
| Week 96, WBC, n=188 | 0.09 ± 1.380 |
| Week 144, WBC, n=185 | -0.12 ± 1.378 |
| Week 192, WBC, n=179 | 0.12 ± 1.412 |
| Week 240, WBC, n=160 | 0.06 ± 1.434 |
| Week 48, Neutrophils, n=191 | 0.08 ± 1.051 |
| Week 96, Neutrophils, n=188 | 0.21 ± 1.184 |
| Week 144, Neutrophils, n=185 | 0.07 ± 1.162 |
| Week 192, Neutrophils, n=179 | 0.26 ± 1.197 |
| Week 240, Neutrophils, n=160 | 0.28 ± 1.194 |
| Week 48, Lymphocytes, n=191 | 0.00 ± 0.438 |
| Week 96, Lymphocytes, n=188 | -0.06 ± 0.511 |
| Week 144, Lymphocytes, n=185 | -0.13 ± 0.422 |
| Week 192, Lymphocytes, n=179 | -0.10 ± 0.442 |
| Week 240, Lymphocytes, n=160 | -0.15 ± 0.483 |
| Week 48, Monocytes, n=191 | -0.032 ± 0.1056 |
| Week 96, Monocytes, n=188 | -0.033 ± 0.1113 |
| Week 144, Monocytes, n=185 | -0.035 ± 0.1244 |
| Week 192, Monocytes, n=179 | -0.025 ± 0.1162 |
| Week 240, Monocytes, n=160 | -0.005 ± 0.1664 |
| Week 48, Eosinophils, n=191 | -0.02 ± 0.114 |
| Week 96, Eosinophils, n=188 | -0.02 ± 0.164 |
| Week 144, Eosinophils, n=185 | -0.04 ± 0.237 |
| Week 192, Eosinophils, n=179 | -0.03 ± 0.248 |
| Week 240, Eosinophils, n=160 | -0.03 ± 0.251 |
| Week 48, Basophils, n=191 | 0.00 ± 0.017 |
| Week 96, Basophils, n=188 | 0.00 ± 0.019 |
| Week 144, Basophils, n=184 | 0.01 ± 0.025 |
| Week 192, Basophils, n=179 | 0.01 ± 0.021 |
| Week 240, Basophils, n=160 | 0.01 ± 0.033 |
| Week 48, Platelets, n=191 | 7.8 ± 31.45 |
| Week 96, Platelets, n=188 | 14.1 ± 32.46 |
| Week 144, Platelets, n=185 | 20.6 ± 42.02 |
| Week 192, Platelets, n=179 | 25.7 ± 42.56 |
| Week 240, Platelets, n=160 | 26.6 ± 38.39 |
Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Grams per liter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=191 | -0.6 ± 10.12 |
| Week 96, n=188 | 0.2 ± 11.63 |
| Week 144, n=185 | 0.9 ± 11.26 |
| Week 192, n=179 | -0.3 ± 12.61 |
| Week 240, n=160 | 1.2 ± 12.71 |
Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Trillion cells per liter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=191 | 0.11 ± 0.306 |
| Week 96, n=188 | 0.13 ± 0.344 |
| Week 144, n=185 | 0.15 ± 0.340 |
| Week 192, n=179 | 0.10 ± 0.363 |
| Week 240, n=160 | 0.12 ± 0.341 |
Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Units per liter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, ALT, n=190 | -23.98 ± 59.452 |
| Week 96, ALT, n=187 | -28.99 ± 56.983 |
| Week 144, ALT, n=185 | -28.99 ± 56.983 |
| Week 192, ALT, n=178 | -31.79 ± 57.955 |
| Week 240, ALT, n=158 | -32.02 ± 63.157 |
| Week 48, AST, n=191 | -14.69 ± 36.674 |
| Week 96, AST, n=188 | -17.97 ± 36.057 |
| Week 144, AST, n=184 | -18.10 ± 36.809 |
| Week 192, AST, n=178 | -19.82 ± 36.312 |
| Week 240, AST, n=158 | -20.24 ± 43.908 |
| Week 48, ALP, n=190 | 10.18 ± 20.288 |
| Week 96, ALP, n=188 | 2.60 ± 28.233 |
| Week 144, ALP, n=185 | -2.20 ± 26.555 |
| Week 192, ALP, n=177 | -0.94 ± 31.604 |
| Week 240, ALP, n=158 | -4.68 ± 27.596 |
| Week 48, GGT, n=190 | -17.88 ± 32.753 |
| Week 96, GGT, n=188 | -22.20 ± 34.866 |
| Week 144, GGT, n=185 | -24.69 ± 39.764 |
| Week 192, GGT, n=175 | -24.07 ± 38.609 |
| Week 240, GGT, n=152 | -27.26 ± 42.932 |
| Week 48 CK, n=188 | 10.51 ± 103.515 |
| Week 96, CK, n=185 | 16.77 ± 141.961 |
| Week 144, CK, n=182 | 5.96 ± 101.897 |
| Week 192, CK, n=173 | 13.72 ± 106.986 |
| Week 240, CK, n=156 | 2.79 ± 105.349 |
| Week 48, LDH, n=187 | -10.62 ± 52.851 |
| Week 96, LDH, n=185 | -10.21 ± 48.112 |
| Week 144, LDH, n=180 | 3.34 ± 73.047 |
| Week 192, LDH, n=172 | -18.45 ± 87.931 |
| Week 240, LDH, n=155 | 25.79 ± 87.464 |
Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Micromoles per liter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, total bilirubin, n=191 | -1.485 ± 7.1347 |
| Week 96, total bilirubin, n=188 | -1.823 ± 6.7167 |
| Week 144, total bilirubin, n=185 | -2.665 ± 7.1281 |
| Week 192, total bilirubin, n=177 | -2.791 ± 6.9230 |
| Week 240, total bilirubin, n=158 | -1.772 ± 6.9786 |
| Week 48, direct bilirubin, n=191 | -0.296 ± 3.1229 |
| Week 96, direct bilirubin, n=188 | -0.462 ± 3.1875 |
| Week 144, direct bilirubin, n=185 | -0.713 ± 3.4898 |
| Week 192, direct bilirubin, n=178 | -0.780 ± 3.5942 |
| Week 240, direct bilirubin, n=157 | -0.599 ± 3.5608 |
| Week 48, serum creatinine, n=191 | 1.03 ± 7.020 |
| Week 96, serum creatinine, n=188 | 1.10 ± 7.597 |
| Week 144, serum creatinine, n=184 | 0.76 ± 9.122 |
| Week 192, serum creatinine, n=178 | 1.37 ± 8.591 |
| Week 240, serum creatinine, n=159 | 1.35 ± 9.879 |
Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Grams per liter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, albumin, n=191 | 1.06 ± 3.063 |
| Week 96, albumin, n=188 | 1.23 ± 3.313 |
| Week 144, albumin, n=185 | 1.86 ± 3.675 |
| Week 192, albumin, n=175 | 1.65 ± 3.780 |
| Week 240, albumin, n=158 | 1.81 ± 3.790 |
| Week 48, total protein, n=191 | -1.01 ± 5.273 |
| Week 96, total protein, n=188 | -0.21 ± 5.397 |
| Week 144, total protein, n=185 | 0.27 ± 5.065 |
| Week 192, total protein, n=175 | -0.94 ± 5.175 |
| Week 240, total protein, n=158 | -1.61 ± 5.829 |
Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridion, phosphorus,calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Millimoles per liter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, BUN, n=191 | -0.046 ± 1.1067 |
| Week 96, BUN, n=188 | 0.000 ± 1.1875 |
| Week 144, BUN, n=184 | 0.037 ± 1.0892 |
| Week 192, BUN, n=178 | 0.143 ± 1.1234 |
| Week 240, BUN, n=155 | 0.131 ± 1.1358 |
| Week 48, Potassium, n=191 | -0.001 ± 0.3703 |
| Week 96, Potassium, n=186 | 0.002 ± 0.3230 |
| Week 144, Potassium, n=184 | -0.039 ± 0.3871 |
| Week 192, Potassium, n=178 | 0.015 ± 0.4223 |
| Week 240, Potassium, n=158 | -0.013 ± 0.3946 |
| Week 48, Sodium, n=191 | 0.21 ± 3.495 |
| Week 96, Sodium, n=186 | -0.02 ± 3.121 |
| Week 144, Sodium, n=184 | 0.35 ± 2.730 |
| Week 192, Sodium, n=178 | 0.38 ± 2.998 |
| Week 240, Sodium, n=158 | -0.13 ± 2.707 |
| Week 48, Chloridion, n=191 | -0.13 ± 3.600 |
| Week 96, Chloridion, n=186 | 0.40 ± 3.535 |
| Week 144, Chloridion, n=183 | 0.35 ± 3.492 |
| Week 192, Chloridion, n=178 | 0.77 ± 3.142 |
| Week 240, Chloridion, n=158 | 0.49 ± 3.364 |
| Week 48, Phosphorus, n=190 | -0.044 ± 0.1724 |
| Week 96, Phosphorus, n=187 | -0.038 ± 0.1632 |
| Week 144, Phosphorus, n=184 | -0.037 ± 0.1955 |
| Week 192, Phosphorus, n=175 | -0.059 ± 0.1876 |
| Week 240, Phosphorus, n=159 | -0.042 ± 0.2009 |
| Week 48, Calcium, n=190 | -0.023 ± 0.1513 |
| Week 96, Calcium, n=187 | -0.006 ± 0.1652 |
| Week 144, Calcium, n=184 | -0.022 ± 0.1605 |
| Week 192, Calcium, n=178 | -0.004 ± 0.1470 |
| Week 240, Calcium, n=158 | -0.006 ± 0.1558 |
| Week 48, Fasting Blood Glucose, n=191 | -0.162 ± 0.7154 |
| Week 96, Fasting Blood Glucose, n=188 | -0.109 ± 0.7139 |
| Week 144, Fasting Blood Glucose, n=185 | -0.094 ± 0.8979 |
| Week 192, Fasting Blood Glucose, n=177 | -0.052 ± 0.7548 |
| Week 240, Fasting Blood Glucose, n=158 | 0.052 ± 1.2197 |
Blood samples were collected to analyze the chemistry parameters: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Milliliter per minute (mL/min) | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=190 | -3.064 ± 11.5995 |
| Week 96, n=188 | -4.214 ± 12.7883 |
| Week 144, n=184 | -4.324 ± 15.3937 |
| Week 192, n=177 | -6.599 ± 13.8858 |
| Week 240, n=155 | -6.658 ± 16.5351 |
Blood samples were collected to analyze the chemistry parameters: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| mL/minute per 1.73 square meter | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Week 48, n=191 | -0.86 ± 6.581 |
| Week 96, n=188 | -0.87 ± 7.078 |
| Week 144, n=185 | -0.68 ± 8.368 |
| Week 192, n=180 | -1.06 ± 8.442 |
| Week 240, n=161 | -1.42 ± 9.609 |
Collected over All cause mortality, non-serious TEAEs and serious TEAEs were collected up to 240 weeks from the start of the treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir Disoproxil Fumarate 300 mg | 2/195 (1%) | 34/195 (17.4%) | 129/195 (66.2%) |
| Event | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 13/195 |
| CholelithiasisHepatobiliary disorders | 2/195 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/195 |
| Ovarian germ cell teratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/195 |
| Foot fractureInjury, poisoning and procedural complications | 1/195 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/195 |
| Post procedural bile leakInjury, poisoning and procedural complications | 1/195 |
| Radius fractureInjury, poisoning and procedural complications | 1/195 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/195 |
| Tibia fractureInjury, poisoning and procedural complications | 1/195 |
| Event | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 36/195 |
| HypophosphataemiaMetabolism and nutrition disorders | 15/195 |
| Urinary tract infectionInfections and infestations | 11/195 |
| Blood creatine phosphokinase increasedInvestigations | 9/195 |
| AnaemiaBlood and lymphatic system disorders | 9/195 |
| HypocalcaemiaMetabolism and nutrition disorders | 7/195 |
| AscitesGastrointestinal disorders | 6/195 |
| ToothacheGastrointestinal disorders | 5/195 |
| CholelithiasisHepatobiliary disorders | 5/195 |
| HypertensionVascular disorders | 5/195 |
Baseline characteristics is presented for modified Intent-to-treat (mITT) Population which consisted of all participants who received at least one dose of study medication. 2 participants did not receive TDF treatment thus excluded from mITT Population
| Age, Continuous(Years) | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Mean | 42.3 ± 9.80 |
| Sex: Female, Male(Participants) | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Female | 47 |
| Male | 148 |
| Race/Ethnicity, Customized(Participants) | Tenofovir Disoproxil Fumarate 300 mg |
|---|---|
| Asian | 195 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Dec 2020, 68 months.
Results were first posted in Feb 2022, 1 year 2 months after primary completion.
Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 68 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir